Noven Pharmaceuticals Inc , was könnte hier noch gehen (50%)???? - 500 Beiträge pro Seite

[js200]

Noven Announces Stock Repurchase Program

Wednesday, March 05, 2003 10:57 ET

MIAMI, Mar 5, 2003 (BUSINESS WIRE) -- Noven Pharmaceuticals, Inc. (Nasdaq:NOVN), a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products, today announced that its Board of Directors has approved a stock repurchase program authorizing the company to buy back up to $25 million of the company`s common stock.

Purchases under the program may be made from time to time in the open market, through block trades, in privately negotiated transactions or otherwise, at the discretion of company management. Depending on market conditions and other factors, purchases may be commenced, suspended or recommenced at any time without prior notice. Noven cannot assure that any shares will be repurchased under the program.

As of February 28, 2003, Noven had approximately 22.6 million common shares outstanding.

About Noven

Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. Together with Novartis Pharmaceuticals Corporation, Noven owns a highly profitable women`s health products company called Novogyne Pharmaceuticals. Noven`s existing products include advanced estrogen transdermal delivery systems (including Vivelle-Dot(R), licensed to Novogyne, and Estradot(R), licensed to Novartis Pharma AG) and combination estrogen/progestin transdermal delivery systems (including CombiPatch(R), licensed to Novogyne, and Estalis(R), licensed to Novartis Pharma AG). With a range of additional products in development, including MethyPatch(R), Noven is committed to becoming the world`s premier developer, manufacturer and marketer of transdermal drug delivery systems. For additional information, visit Noven`s website at http://www.noven.com.

This release contains forward-looking information related to the business of Noven that can be identified by the use of forward-looking terminology such as "may", "will" and similar words and phrases. Such statements are qualified by and subject to the risks and uncertainties specified in Noven`s most recent filings with the Securities and Exchange Commission and those specified herein, including the risk that Noven may not repurchase all or any of the shares authorized because of the market price of Noven`s stock from time to time, other investment opportunities presented to Noven from time to time, Noven`s cash flows from operations, general economic conditions and other factors.


CONTACT: Noven Pharmaceuticals, Inc., Miami
Joseph C. Jones, 305/253-1916

URL: http://www.businesswire.com
Today`s News On The Net - Business Wire`s full file on the Internet
with Hyperlinks to your home page.



Copyright (C) 2003 Business Wire. All rights reserved.


-0-


KEYWORD: FLORIDA
INDUSTRY KEYWORD: MEDICAL
PHARMACEUTICAL
SOURCE:
Noven
Pharmaceuticals,
Inc.


JS200

[js200]

03/05/2003 (11:33 ET) THIRD Business Wire recap for Wed (03/05); stories sent between Wed 10:01 and Wed 11:00 ET (07:01 and 08:00 PT) - Business Wire
03/05/2003 (10:57 ET) Noven Announces Stock Repurchase Program - Business Wire
03/05/2003 (10:50 ET) Noven Pharmaceuticals, Inc. Corrects Date in Press Release, February 28, 2003 Sted February 28, 2002 - Business Wire
03/05/2003 (09:29 ET) Noven Announces Stock Repurchase Program - Business Wire
03/05/2003 (09:24 ET) Noven Announces Stock Repurchase Program - Business Wire

JS200

[js200]

Von Gestern

NOVN
NOVEN PHARMACEUTICALS INC
11.150
+0.650 +6.19%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 2/28/2003 (5) days ago, when the stock price was 10.860. Since then the stock gained 2.67% .

Today the stock closed higher with a higher high and a higher low. The volume is extremely high. The security price is trending up and is overbought.

Candlestick Analysis

Today’s Candlestick Patterns:
Long White Candlestick

Today a Long White Candlestick formed. Buyers were aggressive and buying pressure was strong. Be careful, this may lead to excessive bullishness!

Stock Quote
Last 11.150
Previous Close 10.500
Change +0.650
% Change +6.19%
Volume 574,980
Stock Activity
Open 10.520
Day`s High 11.350
Day`s Low 10.450
52 Week High 27.450
52 Week Low 7.590

Stock Price History
3 Month % Change 12.85
6 Month % Change -14.92
12 Month % Change -44.11
Stock Statistics
50 Day Close MA 8.481
200 Day Close MA 13.180
65 Day Volume MA 251,498

JS200

[Heinerle2]

Ich hoffe, noch viel, da ich engagiert bin *lool*

Greetinxx Heinerle2

[js200]

Research and Markets: Noven Pharmaceuticals(NOVN) - Quantitative Valuation Report
via COMTEX

March 7, 2003

Company Name, Mar 06, 2003 (M2 PRESSWIRE via COMTEX) --

Noven Pharmaceuticals

Now you, as an individual investor or investment professional, can have access to the same tools used by equity fund and portfolio managers as they deal with billions of dollars in assets every business day. Our ongoing cooperative research program, involving economists and financial theorists at Yale University and our own development team, has forged a solid bridge between the academic world and the marketplace. Thus armed with the freshest concepts and ideas, the ValuEngine team tests new theories and works out practical applications for them. We can say without fear of contradiction that there is no asset valuation and forecasting system in use today that is the equal of ValuEngine.

Table of Contents

1. Valuation Overview, 2. ValuEngine Rating, 3. Fair Value, 4.

Investment-Style Rating, 5. Return Forecasts, 6. Market Ratio-Based Valuation, 7. Quantitative Summary, 8. Comparisons, 9. Earnings Report, 10. Analyst Expectations, 11. Annual Financials, 12. Quarterly Financials

For a complete index of this report click on http://www.researchandmarkets.com/reports/14733" target="_blank" rel="nofollow ugc noopener">http://www.researchandmarkets.com/reports/14733

Independent, numbers-based, objective Equity Research

Use this report to help to :

- Optimize your equity portfolio for the best risk/return ratio.

- Forecast equity portfolio`s value next year.

- Find a fair value for stocks and forecast their future prospects.

- Determine the chances of gain or loss on current holdings.

- Find momentum &volatility ranks for stocks.

`Yale finance professor Dr. Zhiwu Chen has done an excellent job of transforming academic research and rigorous mathematics into a practical investing tool. The valuation model combines 12-month trailing EPS, consensus analyst estimates, and the 30-year Treasury yield to come up with a fair value price for any stock. Then its forecast model uses common market trends such as momentum and price reversals, and runs simulations to determine the most probable price outcomes over three years.`- Forbes

Note on the Models used to create the reports:

These company reports employ many proprietary models, which were adapted from innovative concepts in finance theory generated both in academia and from Wall Street practice. Each of the four ValuEngine models represents the state-of-the-art in valuation, forecasting technologies:

1) The VE Stock Valuation Model 2) The VE Stock Forecast Model 3) The VE Portfolio Advisor Model 4) The VE Portfolio Forecast Model

The ValuEngine Stock Valuation Model

The ValuEngine Stock Valuation Model was derived from the recent research and findings of Dr. Zhiwu Chen, Professor of Finance, Yale University, and his co-authors. The model is more sophisticated than traditional valuation models and outperforms its peers by employing a three-factor approach to stock valuation. Fundamental variables such as a company`s trailing 12-month Earnings-Per-Share (EPS), the analyst consensus estimate of the company`s future 12-month EPS, and the 30-year Treasury yield are all combined and used to create a more accurate reflection of a company`s fair value. Armed with these framework features, the Model then paints a detailed picture of a company`s fair value, which is represented by the `model price.`

The ValuEngine Stock Forecast Model

The predictive variables used in the forecasting models include both proprietary and well-established forecasting variables derived from credible financial research studies and publications. They use a distinct forecasting model for each forecasting horizon and every industry. The forecasting models capture, among other things, several important tendencies that stock prices consistently exhibit: Short-term price reversals Intermediate-term momentum continuation Long-term price reversals. They then apply the most advanced statistical/econometric techniques to ensure that the stock return forecasts are as reliable as possible. In addition, they have a realistic econometric model for assessing a stock`s and a portfolio`s future return prospects. This econometric model involves running thousands of simulations to estimate the probability of a double in stock price as well as the probability of meeting and exceeding any given investment target by a stock or a portfolio of stocks.

The ValuEngine Portfolio Forecast Model

The PortfolioForecast tool arrives at projections by utilizing forecasting models to estimate future returns for the individual stocks in a portfolio. After computing the future return forecasts for each stock, they then run thousands of concurrent simulations for all of the stocks in a given portfolio (subject to various econometric requirements). The thousands of simulated price paths created by this process form the basis for the PortfolioForecast projections. Finally, the PortfolioForecast tool calculates the most likely return forecast from the thousands of simulated outcomes.

The ValuEngine Portfolio Advisor Model

The ValuEngine PortfolioAdvisor enables you to specify the following portfolio objectives: Maximize the chance of meeting or exceeding an investment target; Minimize the chance of loss; Both of the above.

Choosing the first option will prompt PortfolioAdvisor to create an aggressive yet risky portfolio. Choosing the second option will prompt PortfolioAdvisor to search for a conservative mix of stocks that will seek to preserve capital. Choosing the third option will prompt PortfolioAdvisor to create a balanced portfolio that will seek to both maximize potential gains and minimize potential losses. Once you have specified an investment objective, PortfolioAdvisor will utilize our forecasting models to estimate future returns for the individual stocks in your portfolio. PortfolioAdvisor will then examine tens of thousands of possible capital allocation plans distributed across the stocks of your choice. From the results of these simulations, PortfolioAdvisor will identify and display the most favorable stock allocation for your portfolio. Additionally, PortfolioAdvisor will inform you of the exact number of shares to buy or sell of each stock so that the resulting portfolio will maximize your chances of maximizing gain, minimizing loss, or both.

Back Testing

Every valuation, forecasting, and advisory model has been extensively back-tested in the United States, Hong Kong, and Taiwan equities markets.

The investment performance of each model has been proven to exceed that of many well-known stock-picking styles.

Report Pricing:

Electronic EUR 24 (US$ 22).

ORDERING INFORMATION - FIVE EASY WAYS TO PLACE YOUR ORDER:

ORDER ONLINE: To order this report please click on http://www.researchandmarkets.com/reports/14733" target="_blank" rel="nofollow ugc noopener">http://www.researchandmarkets.com/reports/14733 ORDER VIA EMAIL: mailto:[e-mail] ORDER VIA FAX-BACK FORM: Click on http://www.researchandmarkets.com/reports/14733" target="_blank" rel="nofollow ugc noopener">http://www.researchandmarkets.com/reports/14733 Fax to [phone] ORDER VIA POST: Click on http://www.researchandmarkets.com/reports/14733" target="_blank" rel="nofollow ugc noopener">http://www.researchandmarkets.com/reports/14733 Mail to Research and Markets Ltd., Guinness Centre, Taylors Lane, Dublin 8, Ireland ORDER VIA PHONE: Telephone: [phone]

REPORT DATA SUMMARY:

Noven Pharmaceuticals(NOVN) - Quantitative Valuation Report Publisher Name: ValuEngine, Inc.

Date Published: 2/4/2003 Number of Pages: 18 Category: Company Reports URL: www.researchandmarkets.com/reports/14733

About Research and Markets Ltd.

Research and Markets Ltd. are Europe`s largest resource for industry and market research reports. R&M distribute thousands of major research publications from the world`s leading publishers, consultants and market analysts. R&M provide you with the latest forecasts on international and regional markets, key industries, the top companies, new products and the latest market trends and forecasts.

Major sectors covered include: Banking, Insurance, Pensions, Financial Services, Biotechnology, Genomics, General Business, Advertising, Marketing, Management, Personnel, Company Reports, Competitive Intelligence, Market Intelligence, Strategic Planning, Top 100 Company Lists, Computing, Advanced Technology, Hardware, Software, Construction, Engineering, Consumer, Personal Care, Clothing, Fashion, Household, Furniture, Country Reports (North American, South American, Europe, Africa, China, Asia Pacific, and Middle East), Demographics (Generational and Lifestyle), Energy, Natural Resources, Environmental, Gas, Oil, Power, Mining, Food, Beverage, Agriculture, Food Service, Government, Public Sector, Aerospace, Defence, Education, Healthcare, Medical Devices, Diagnostics, Hospital, Internet, E-Commerce, E-Business, IT Security, New Media, Manufacturing, Industry, Supply Chain and Logistics, Media, Entertainment, Broadcast, Cable, Gaming, Pharmaceuticals, Drug Delivery, Process Industry, Advanced Materials, Chemicals, Paper, Plastics, Retailing, Services Sector, Travel, Telecommunications, Networks, Satellite, Mobile and Wireless, Transport, Shipping, Automotive, and Aviation

For additional information on ResearchandMarkets.com, their range of reports or their value-added services, visit their web site at http://www.researchandmarkets.com or [e-mail]

CONTACT: Holly Swift, Public Relations Manager, Research, Research and Markets Ltd. e-mail: [e-mail]

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [e-mail].

(C)1994-2003 M2 COMMUNICATIONS LTD

Print story

Current Quote

NSD: NOVN
Biotech/Medical

Last: 12.300
Change: N/A
Volume: N/A
Day High: N/A
Day Low: N/A



First Alert News
Get real-time NOVN release alerts by entering your email address below.

JS200

[js200]

Von Gestern

NOVN
NOVEN PHARMACEUTICALS INC
12.300
+1.150 +10.31%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 2/28/2003 (6) days ago, when the stock price was 10.860. Since then the stock gained 13.26% .

Today the stock closed higher, close to its high (sign of strength) with a higher high and a higher low. The volume is extremely high. The security price is trending up and is overbought.

Candlestick Analysis

Today’s Candlestick Patterns:
Long White Candlestick

Today a Long White Candlestick formed. Buyers were aggressive and buying pressure was strong. Be careful, this may lead to excessive bullishness!

Stock Quote
Last 12.300
Previous Close 11.150
Change +1.150
% Change +10.31%
Volume 821,134
Stock Activity
Open 11.200
Day`s High 12.400
Day`s Low 11.000
52 Week High 27.450
52 Week Low 7.590

Stock Price History
3 Month % Change 23.62
6 Month % Change -8.07
12 Month % Change -38.50
Stock Statistics
50 Day Close MA 8.539
200 Day Close MA 13.133
65 Day Volume MA 261,608

JS200

[Heinerle2]

Habe meine gestern Nacht bei 12.20 verloren, war nett.

Greetinxx Heinerle2

[Heinerle2]

*Grummel*, war wohl etwas zu früh....

Greetinxx Heinerle2

[js200]

MORNING UPDATE: Man Securities Issues Alerts for GE, AMGN, DDS, TIVO, and NOVN
via COMTEX

March 7, 2003

CHICAGO, Mar 7, 2003 /PRNewswire via COMTEX/ --

Man Securities issues the following Morning Update at 8:30 AM EST with new PriceWatch Alerts for key stocks.

(Photo: http://www.newscom.com/cgi-bin/prnh/20020214/MANSECLOGO )

Before the open ... PriceWatch Alerts for GE, AMGN, DDS, TIVO, and NOVN, Put/Call Alert, FuturesWatch, Today`s Economic Calendar, and the Quote Of The Day.

QUOTE OF THE DAY

`Discretion is the better part of valor: Sell first and worry about it later. Economic indicators are still taking a backseat to what goes on in Iraq.`

-- Michael Driscoll, stock trader, brokerage firm Bear Stearns New PriceWatch Alerts for GE, AMGN, DDS, TIVO, and NOVN ... PRICEWATCH ALERTS - HIGH RETURN COVERED CALL OPTIONS -- General Electric Co. (NYSE: GE) Last Price 23.95 - APR 25 CALL OPTION@ $0.65 -> 7.3 % Return assigned* -- Amgen Inc. (Nasdaq: AMGN) Last Price 55.40 - APR 55 CALL OPTION@ $2.70 -> 4.4 % Return assigned* -- Dillard`s, Inc. (NYSE: DDS) Last Price 13.50 - MAY 12.50 CALL OPTION@ $1.70 -> 5.9 % Return assigned* -- TiVo Inc. (Nasdaq: TIVO) Last Price 6.29 - AUG 5 CALL OPTION@ $1.85 -> 12.6 % Return assigned* -- Noven Pharmaceuticals Inc. (Nasdaq: NOVN) Last Price 13.31 - JULY 12.50 CALL OPTION@ $1.70 -> 7.7 % Return assigned*
*For our report on `5 Dividend paying stocks with double digit returns`, go to: www.investorsobserver.com/5div

** Your essential daily briefing on the state of the world and what it means to the stock market. FREE for 15 days. Fill out a 5 question survey and it`s yours: www.investorsobserver.com/ftmu

NOTE: All stocks and options shown are examples only. These are not recommendations to buy or sell any security.

MARKET OVERVIEW

Overseas markets are reacting in unanimity to President Bush`s speech of last evening, as none of the 15 markets that we track are positive. The cumulative average return on the group stands at a minus 1.671 percent. Personally, I learned nothing new from the President`s speech, except for the fact that his resolve is as strong as ever. It was Mr. Bush`s avoidance to answer certain questions that demonstrated this resolve. His focus was from point A to point B and the lack of a direct answer was replaced with a reiteration of his fundamental goals. It appears as if the markets viewed that speech as the `silence before the storm.`Just when you think your local market is bad, along comes the Nikkei to set a fresh 20-year low. The Japanese stock market exited the week 2.6 percent lighter. This is an extremely poor time to hover around historic lows, as the country`s fiscal year will come to an end at the terminus of the month. A lot of the net worth of Japanese banks is hinged upon the value of the market. Concerning our friends north of the border, the Canadian jobless rate held at 7.4 percent from January to February. The labor force advanced by 54,500 during the month, while total employment rose by 55,200 (that is why the unemployment rate held constant).

Forget about earnings for the moment, today. A key piece of economic data with market moving potential will be out before the open (so if you are still in the game, your bet will have to ride). February Non-Farm Payrolls are expected to have risen by an anemic 5,000 following last month`s surprise surge of 143,000. In my humble opinion, if you are not seeing monthly increases over 150,000, you are not witnessing economic expansion. The February Unemployment Rate s expected to have advanced to 5.8 percent from the 5.7 percent of January. Federal Reserve Chairman Greenspan speaks on global finance at the Banque de France Symposium in Paris around 9:45 (just thought you should know). You will want to be in touch at 10:00 a.m. as United Nations Inspectors Blix and ElBaradei report to the U.N. Security Council. There could be some overhang from Intel`s mid-quarter update which came out after the market close yesterday. The chipmaker said it expects first-quarter sales of $6.6 billion to $6.8 billion. This range represents a narrowing of the prior sales range of between $6.5 billion and $7 billion. Most analysts had expected Intel to leave the upper figure of its revenue- estimate range in place while lifting the low end. Analysts, on average, had predicted earnings of 12 cents a share on revenue of $6.75 billion. The company itself does not provide targets for net income or earnings per share. In extended trading last evening the shares traded as low as $15.85, over five percent below its regular session close of $16.70.

Be prepared for the investing week ahead with Bernie Schaeffer`s FREE Monday Morning Outlook. For more details and to sign up go to: http://www.schaeffersresearch.com/redirect.asp?CODE=GJ01A3&P…

PUT/CALL ALERT

Equity option activity on the CBOE yesterday had 267,675 put contracts trade compared to 309,870 call contracts. The resultant 0.864 put/call ratio has moved the 21-day moving average up to 0.760. The CBOE Market Volatility Index (VIX - 36.34) exploded to the upside by 6.16 percent and the Nasdaq 100 Trust Volatility Index (QQV - 39.59) added 3.21 percent.

FUTURES WATCH

The futures markets are lower this morning after the President`s speech has investors concluding that war is almost inevitable. The futures markets are trading below this week`s current low. The unemployment number came out as expected but the non-farm payroll was considerably lower than expected which is also helping to put pressure on the market. It looks as if the S&P futures are on the way back to test the 80500 low from February 13th. Every rally has been short covering in nature and just another opportunity to get short the markets. It seems like many of the funds have left the equities in favor of the interest rates and foreign currencies.

*For a free Trader`s Resource CD click the following link or paste it into your browser address bar: http://www.manfutures.com/mucd.html

TODAY`S ECONOMIC CALENDAR 8:30 a.m.: February Non-Farm Payrolls (last plus 143,000). 8:30 a.m.: February Unemployment Rate (last 5.7 percent). 9:45 a.m.: Federal Reserve Chairman Greenspan speaks on global finance at the Banque de France Symposium in Paris. 10:00 a.m.: United Nations Inspectors Blix, ElBaradei report to the Security Council. 2:30 p.m.: Federal Reserve Governor Gramlich speaks at the Neighborhood Housing Services luncheon in Anaheim Calif. 3:00 p.m.: January Consumer Credit (last minus $4.0 billion).
Man Financial Inc is one of the world`s major futures and options brokers and has been recognized as a leading option order execution firm for individuals and institutions. Member CBOE/NASD/SIPC (CRD#6731). For more information and a free CD with educational tools to help you invest smarter, see http://www.mansecurities.com/mu.html .

This Morning Update was prepared with data and information provided by:

InvestorsObserver.com -- Better Strategies for Making Money -> For Investors With a Sense of Humor. Only $1 for your first month plus seven free bonuses worth over $320, see: www.investorsobserver.com/18ways

Schaeffer`s Investment Research -- Sign up for your FREE e-weekly, Monday Morning Outlook, Bernie Schaeffer`s look ahead at the markets. Sign Up Now http://www.schaeffersresearch.com/redirect.asp?CODE=GJ01A3&P…

All stocks and options shown are examples only. These are not recommendations to buy or sell any security and they do not represent in any way a positive or negative outlook for any security. Potential returns do not take into account your trade size, brokerage commissions or taxes which will affect actual investment returns. Stocks and options involve risk and are not suitable for all investors and investing in options carries substantial risk. Prior to buying or selling options, a person must receive a copy of Characteristics and Risks of Standardized Options available from Sharon at 800-837-6212 or at http://www.cboe.com/Resources/Intro.asp . Privacy policy available upon request.

SOURCE Man Securities

Michael Lavelle of Man Securities, [phone] /Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020214/MANSECLOGO AP Archive: http://photoarchive.ap.org PRN Photo Desk, [phone] or [phone]

http://www.mansecurities.com/mu.html

Copyright (C) 2003 PR Newswire. All rights reserved.

JS200

[js200]

03/07/2003 (09:35 ET) MORNING UPDATE: Man Securities Issues Alerts for GE, AMGN, DDS, TIVO, and NOVN - PR Newswire
03/07/2003 (07:11 ET) Research and Markets: Noven Pharmaceuticals(NOVN) - Quantitative Valuation Report - M2 Communications
03/06/2003 (15:06 ET) VOLUME(+): NOVN Volume 61% > 20-adsv, Stock +9.24% - Knobias
03/06/2003 (06:02 ET) NOVN CEO to Speak at Smith Barney Pharmaceutical Conf. - Knobias
03/05/2003 (11:33 ET) THIRD Business Wire recap for Wed (03/05); stories sent between Wed 10:01 and Wed 11:00 ET (07:01 and 08:00 PT) - Business Wire


JS200

[js200]

@HEINERLE

Hast dich wohl nicht getraut

NOVEN PHARMACEUTICALS - Nasdaq National Market: NOVN

Consolidated Real-time Market Quote*
Last Change (%) After Hours Chg (%)** Bid Ask Trade Time
12.80 0.5 (4.07) 0.01 (0.08) 12.56 (5.80) 12.85 (10) 15:59

Exchange QuoteLast Change (%) Bid (size) Ask (size) Trade Time
12.79 0.49 (3.98) 12.71 (3) 12.80 (5) 15:59
Day Volume Last Size Open High Low
646,267 500 12.15 13.22 11.96
Latest Ticks # of Trades Avg Trade Size 52 Wk High 52 Wk Low
-=-+ 907 713 27.51 7.30
Prev Close Avg Day Vol
12.30 403,800

JS200

[Heinerle2]

@11: Hatte die Teile deutlich unter 10 einstehen, daher wars ok - habe dafür VaxGen gekauft

Greetinxx Heinerle2

[js200]

Von Gestern ( 200ter TAGESLINIE fast erreicht, Rückschlag nicht auszuschliessen )

NOVN
NOVEN PHARMACEUTICALS INC
12.799
+0.499 +4.06%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 2/28/2003 (7) days ago, when the stock price was 10.860. Since then the stock gained 17.85% .

Today the stock closed higher with a higher high and a higher low. The volume is extremely high. The security price is trending up and is overbought.

Candlestick Analysis

Today’s Candlestick Patterns:
Long White Candlestick

Today a Long White Candlestick formed. Buyers were aggressive and buying pressure was strong. Be careful, this may lead to excessive bullishness!

Stock Quote
Last 12.799
Previous Close 12.300
Change +0.499
% Change +4.06%
Volume 651,767
Stock Activity
Open 12.150
Day`s High 13.220
Day`s Low 11.960
52 Week High 27.450
52 Week Low 7.590

Stock Price History
3 Month % Change 28.76
6 Month % Change 2.72
12 Month % Change -38.70
Stock Statistics
50 Day Close MA 8.614
200 Day Close MA 13.084 Wird hart zum nehmen
65 Day Volume MA 268,706

JS200

[js200]

03/10/2003 (06:40 ET) Research and Markets: Noven Pharmaceuticals(NOVN) - Quantitative Valuation Report - M2 Communications
03/07/2003 (09:35 ET) MORNING UPDATE: Man Securities Issues Alerts for GE, AMGN, DDS, TIVO, and NOVN - PR Newswire
03/07/2003 (07:11 ET) Research and Markets: Noven Pharmaceuticals(NOVN) - Quantitative Valuation Report - M2 Communications
03/06/2003 (15:06 ET) VOLUME(+): NOVN Volume 61% > 20-adsv, Stock +9.24% - Knobias
03/06/2003 (06:02 ET) NOVN CEO to Speak at Smith Barney Pharmaceutical Conf. - Knobias

JS200

[js200]

Von Gestern

NOVN
NOVEN PHARMACEUTICALS INC
11.960
-0.180 -1.48%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 2/28/2003 (11) days ago, when the stock price was 10.860. Since then the stock gained 10.13% .

Today the stock closed lower, at its low (sign of weakness) with a lower high and a lower low. The volume is normal. The security price is trending up and is overbought.

Candlestick Analysis

Today’s Candlestick Patterns:
Long Black Candlestick

Today a Long Black Candlestick formed. Sellers were aggressive and selling pressure was strong. Be careful, this may be a potential turning point!

Stock Quote
Last 11.960
Previous Close 12.140
Change -0.180
% Change -1.48%
Volume 262,944
Stock Activity
Open 12.220
Day`s High 12.490
Day`s Low 11.960
52 Week High 27.450
52 Week Low 7.590

Stock Price History
3 Month % Change 21.66
6 Month % Change -4.93
12 Month % Change -40.94
Stock Statistics
50 Day Close MA 8.708
200 Day Close MA 12.973
65 Day Volume MA 273,971

JS200

[Heinerle2]

...war doch nicht so dämlich, Noven in VaxGen zu tauschen *händereib*

Greetinxx Heinerle2

[js200]

@HEINERLE

Vaxgen sind Heute toll gelaufen, nur dieses spricht auch Bände (ob da die 50% von heute helfen ?????)

VXGN 52 Week High: 23.250 52 week Low: 2.760

NOVN 52 Week High: 27.510 52 week Low: 7.300

JS200

[Heinerle2]

@17: Ist schon klar, für den Moment war es aber ok. Ich werde VaxGen heute evtl. auch verkaufen, reicht mir eigentlich *g*.

Greetinxx Heinerle2

[Heinerle2]

VaxGen zur Eröffnung verkauft, habe mir dafür ein paar Xenova gegönnt *gg*

Greetinxx Heinerle2

[js200]

Noven Discloses Development Programs for Fentanyl and Dextroamphetamine Transdermal Systems
via COMTEX

March 24, 2003

MIAMI, Mar 24, 2003 (BUSINESS WIRE) --

Noven Pharmaceuticals, Inc. (Nasdaq:NOVN), a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products, today announced development programs for two new transdermal systems.

Fentanyl. Noven has completed bioequivalence studies comparing its developmental fentanyl transdermal system to Duragesic(R), a Schedule II opioid analgesic transdermal system for chronic pain distributed by Janssen Pharmaceutica, L.P., a division of Johnson &Johnson. U.S. sales for Duragesic(R) exceeded $900 million in 2002. Noven believes it is one of several companies developing a generic version of Duragesic(R). Duragesic(R) is expected to come off patent in July 2004, but Janssen has been granted an additional six months pediatric exclusivity, which would effectively prevent the launch of a generic version until January 2005.

Noven`s fentanyl transdermal patch utilizes a solid-state drug/adhesive matrix, as opposed to the liquid reservoir delivery system used in Duragesic(R). Noven has also developed transdermal formulations for several additional pain management compounds.

`We expect to file an Abbreviated New Drug Application for our fentanyl patch with the Food and Drug Administration in the second half of 2003, and we are actively exploring opportunities with companies interested in marketing the product,`said Robert Strauss, Noven`s President, CEO &Chairman.

Dextroamphetamine. Noven also announced that it expects to begin human clinical trials of a long-acting dextroamphetamine transdermal system for Attention Deficit Hyperactivity Disorder (ADHD) in the summer of 2003. The dextroamphetamine patch adds to Noven`s ADHD therapy development program, which includes a methylphenidate transdermal system (MethyPatch(R)), currently under FDA review. In February 2003, Noven announced that Shire Pharmaceuticals Group plc, the market-share leader in ADHD therapy, had agreed to acquire global marketing rights to MethyPatch.

`Our developmental dextroamphetamine patch has the potential to be the first transdermal therapy in the $700 million U.S. market for amphetamine-based ADHD products,`said Strauss. `It would give Noven product entries in both the methylphenidate and amphetamine segments of the ADHD therapy market.`

Growth Strategy. Strauss added: `Our fentanyl and dextroamphetamine patches should advance our strategy to leverage our DOT Matrix(TM) transdermal technology across a diverse range of products and therapeutic categories. These products, along with the roughly 20 other transdermal products that Noven has formulated, should position Noven for growth from diverse sources in the years ahead.`

DOT Matrix technology permits Noven to deliver predictable therapeutic doses of a wide range of prescription drugs through discreet, comfortable and adherent patches that are well suited to active lifestyles.

About Noven

Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. Together with Novartis Pharmaceuticals Corporation, Noven owns a profitable women`s health products company called Novogyne Pharmaceuticals. Noven`s existing products include advanced estrogen transdermal delivery systems (including Vivelle-Dot(R), licensed to Novogyne, and Estradot(R), licensed to Novartis Pharma AG) and combination estrogen/progestin transdermal delivery systems (including CombiPatch(R), licensed to Novogyne, and Estalis(R), licensed to Novartis Pharma AG). With a range of additional products in development, including MethyPatch(R) for ADHD, Noven is committed to becoming the world`s premier developer, manufacturer and marketer of transdermal drug delivery systems. For additional information, visit Noven`s website at http://www.noven.com.

Duragesic(R) is a registered trademark of Janssen Pharmaceutica, L.P.

This release contains forward-looking information related to the business of Noven that can be identified by the use of forward-looking terminology such as `believes,``expects,``may,``could,` `potential,``would,``should`and similar words and phrases. Such statements are qualified by and subject to the risks and uncertainties specified in Noven`s most recent filings with the Securities and Exchange Commission and those specified herein, including the risk that: we may fail to develop new products or establish new strategic collaborations, either of which would significantly limit our ability to leverage our technology, diversify our prospects and execute on our growth strategy; product development is inherently risky, and any project, including our dextroamphetamine or fentanyl patches, could fail at any time or be delayed indefinitely; the timing of ANDA approval for our fentanyl patch could be affected by any number of issues that are beyond our control, including patent strategies by the innovator and strategies by generic competitors that could result in exclusivity; with several companies expected to offer a generic version of Duragesic, product pricing and other competitive factors may substantially diminish the market opportunity available to Noven; the Shire transaction may not close; and MethyPatch may not be approved or, if approved, it may not be successfully commercialized by Shire due to competitive market conditions or other factors, including physician/patient preferences for other ADHD therapies.

Noven Pharmaceuticals, Inc., Miami Investor &Media Contact: Joseph C. Jones, 305/253-1916 or Product Licensing Inquiries: Pavan Handa, 305/964-3330

http://www.businesswire.com

Today`s News On The Net - Business Wire`s full file on the Internet with Hyperlinks to your home page.

Copyright (C) 2003 Business Wire. All rights reserved.


JS200

[js200]

03/24/2003 (08:34 ET) Noven Discloses Development Programs for Fentanyl and Dextroamphetamine Transdermal Systems - Business Wire
03/21/2003 (16:11 ET) New 10-K just released for NOVN - Edgar
03/10/2003 (06:40 ET) Research and Markets: Noven Pharmaceuticals(NOVN) - Quantitative Valuation Report - M2 Communications
03/07/2003 (09:35 ET) MORNING UPDATE: Man Securities Issues Alerts for GE, AMGN, DDS, TIVO, and NOVN - PR Newswire
03/07/2003 (07:11 ET) Research and Markets: Noven Pharmaceuticals(NOVN) - Quantitative Valuation Report - M2 Communications


JS200

[js200]

03/25/2003 (13:02 ET) CONF: NOVN To Present At BOA Healthcare Conference @ 15:45 ET - Knobias
03/24/2003 (11:38 ET) Noven to Present March 25 at Banc of America Securities Healthcare Conference; Public Invited to Listen to Presentation Via Webcast - Business Wire
03/24/2003 (08:34 ET) Noven Discloses Development Programs for Fentanyl and Dextroamphetamine Transdermal Systems - Business Wire
03/21/2003 (16:11 ET) New 10-K just released for NOVN - Edgar
03/10/2003 (06:40 ET) Research and Markets: Noven Pharmaceuticals(NOVN) - Quantitative Valuation Report - M2 Communications

JS200

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


03/25/2003 (13:02 ET) CONF: NOVN To Present At BOA Healthcare Conference @ 15:45 ET - Knobias



03/24/2003 (11:38 ET) Noven to Present March 25 at Banc of America Securities Healthcare Conference; Public Invited to Listen to Presentation Via Webcast - Business Wire



03/24/2003 (08:34 ET) Noven Discloses Development Programs for Fentanyl and Dextroamphetamine Transdermal Systems - Business Wire



03/21/2003 (16:11 ET) New 10-K just released for NOVN - Edgar



03/10/2003 (06:40 ET) Research and Markets: Noven Pharmaceuticals(NOVN) - Quantitative Valuation Report - M2 Communications



03/07/2003 (09:35 ET) MORNING UPDATE: Man Securities Issues Alerts for GE, AMGN, DDS, TIVO, and NOVN - PR Newswire



03/07/2003 (07:11 ET) Research and Markets: Noven Pharmaceuticals(NOVN) - Quantitative Valuation Report - M2 Communications



03/06/2003 (15:06 ET) VOLUME(+): NOVN Volume 61% > 20-adsv, Stock +9.24% - Knobias



03/06/2003 (06:02 ET) NOVN CEO to Speak at Smith Barney Pharmaceutical Conf. - Knobias



03/05/2003 (11:33 ET) THIRD Business Wire recap for Wed (03/05); stories sent between Wed 10:01 and Wed 11:00 ET (07:01 and 08:00 PT) - Business Wire



03/05/2003 (10:57 ET) Noven Announces Stock Repurchase Program - Business Wire



03/05/2003 (10:50 ET) Noven Pharmaceuticals, Inc. Corrects Date in Press Release, February 28, 2003 Sted February 28, 2002 - Business Wire



03/05/2003 (09:29 ET) Noven Announces Stock Repurchase Program - Business Wire



03/05/2003 (09:24 ET) Noven Announces Stock Repurchase Program - Business Wire



03/03/2003 (15:16 ET) VOLUME(-): NOVN Volume 63% > 20-adsv, Stock -1.29% - Knobias



03/03/2003 (13:30 ET) Noven to Present March 6 at Salomon Smith Barney Specialty Pharmaceuticals Conference; Public Invited to Listen to Presentation Via Webcast - Business Wire



03/03/2003 (07:02 ET) ERN/CALL: NOVN To Hold Q4 Conf Call @ 10:00 ET Today - Knobias



02/28/2003 (16:59 ET) New 8-K just released for NOVN - Edgar



02/28/2003 (10:51 ET) VOLUME(+): NOVN Volume 11% > 20-adsv, Stock +3.54% - Knobias



02/28/2003 (10:01 ET) RATING(+): CE Unterberg Ups NOVN to LT Buy from LT Mkt Perforn - Knobias



02/28/2003 (09:13 ET) WSNA ACTIVE STOCK ALERT: GENG, CLCI, NOVN, PAHG - Financial News USA



02/28/2003 (06:40 ET) MEDIA: Today`s Wall Street Journal Mentions NOVN - Knobias



02/28/2003 (06:30 ET) MEDIA: Today`s Wall Street Journal Mentions NOVN - Knobias



02/27/2003 (10:06 ET) VOLUME(+): NOVN Volume 117% > 20-adsv, Stock +24.37% - Knobias



02/27/2003 (09:46 ET) ERN(+): NOVN/Q4 13c vs 16c; Beats Q Est; Provides Guidance - Knobias

JS200

[js200]

http://www.knobias.com/individual/public/quote.htm?ticker=NO…

JS200

[js200]

StockDiagnostics.com Reiterates Noven`s OPS Rating of `3`
via CDS

March 27, 2003

StockDiagnostics.com announced that it has reiterated its OPS Rating of `3`for Noven Pharmaceuticals Inc (NASDAQ:NOVN). Noven Pharmaceuticals has had an OPS Rating of `3`for four consecutive quarters.


StockDiagnostics.com`s maintaining of the OPS RatingTM is based on Noven Pharmaceuticals`recently filed Cash Flow Statements for its quarter ended December 31, 2002. The company`s computed OPS TM (Operational-cashflow Per Share) for the quarter was $0.52 per share as compared to $0.12 per share for the comparable year earlier quarter. OPS for the most recent 12 months ended December 31, 2002 was $0.52 per share as compared to $0.52 per share for the 12 months ended December 31, 2001. OPS for Noven Pharmaceuticals`trailing twelve months reached a two year high.

The shares of Noven Pharmaceuticals were recently trading at $13.28.

About OPS RatingsTM -- StockDiagnostics.com monitors a public company`s Operational cash flow Per Share (`OPS`) and assigns it an `OPS Rating`, which measures the long term risk associated with a company`s ability to remain in business. A company`s `OPS`logically falls into a mathematical sequence that ranks it into one of eight distinctive `risk`categories. Each of the categories is based on a company`s operating cash flow for each of its last 4 quarters and its cumulative operating cash flow for its most recent 12 months. OPS Ratings are upgraded, downgraded or reiterated each time a company files a quarterly report and at any time that its financial statements are amended. Statistical research on OPS Ratings is available at http://www.StockDiagnostics.com/marketnews." target="_blank" rel="nofollow ugc noopener">http://www.StockDiagnostics.com/marketnews.

About StockDiagnostics.com -- StockDiagnostics.com has a proprietary data refinery that automates the process of collecting, sorting and organizing large amounts of securities pricing and financial data into comparative financial ratios. These ratios are used to identify Financial Statement anomalies and securities pricing variances to monitor changes in the performance of public companies. Go to http://www.StockDiagnostics.com/marketnews for a description of StockDiagnostics.com`s patent-pending technical applications, such as OPS, OPS Ratings, The EPS Syndrome and more. Full details are available at http://www.StockDiagnostics.com/marketnews." target="_blank" rel="nofollow ugc noopener">http://www.StockDiagnostics.com/marketnews.

JS200

[js200]

03/26/2003 (16:10 ET) New 10-K/A just released for NOVN - Edgar
03/25/2003 (13:02 ET) CONF: NOVN To Present At BOA Healthcare Conference @ 15:45 ET - Knobias
03/24/2003 (11:38 ET) Noven to Present March 25 at Banc of America Securities Healthcare Conference; Public Invited to Listen to Presentation Via Webcast - Business Wire
03/24/2003 (08:34 ET) Noven Discloses Development Programs for Fentanyl and Dextroamphetamine Transdermal Systems - Business Wire
03/21/2003 (16:11 ET) New 10-K just released for NOVN - Edgar

JS200

[js200]

Last Trade: 14.070 Change: 0.550 (+4.068%)
Previous Close: 13.520 Volume: 291,800
Bid: 14.060 Ask: 14.060
Today`s Open: 13.510 # of Trades: 878

JS200

[js200]

30% hätten wir, ist doch nicht schlecht

JS200

[js200]

Von Gestern

NOVN
NOVEN PHARMACEUTICALS INC
14.340
+0.820 +6.07%


Daily Commentary
BUY

Our system recommends BUY as of today. Previous SELL recommendation was made on 3/27/2003 (0) days ago, when the stock price was 14.340. Since then the stock gained 0.00% .

Today the stock closed higher, close to its high (sign of strength) with a higher high and a higher low. The volume is high. The security price is trending up and is overbought.


The correction was very short, and the stock continues its rally. It is again time for bulls. Short positions should be closed immediately. Buy this stock now and hold it until the next sell signal. Long-term trend is bullish.

Candlestick Analysis

Today’s Candlestick Patterns:
Long White Candlestick

Today a Long White Candlestick formed. Buyers were aggressive and buying pressure was strong. Be careful, this may lead to excessive bullishness!

Stock Quote
Last 14.340
Previous Close 13.520
Change +0.820
% Change +6.07%
Volume 399,137
Stock Activity
Open 13.510
Day`s High 14.500
Day`s Low 13.360
52 Week High 27.450
52 Week Low 7.590

Stock Price History
3 Month % Change 54.69
6 Month % Change 20.40
12 Month % Change -31.22
Stock Statistics
50 Day Close MA 9.713
200 Day Close MA 12.220
65 Day Volume MA 296,511

JS200

[js200]

Von Gestern

NOVN
NOVEN PHARMACEUTICALS INC
14.520
+0.180 +1.26%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 3/28/2003 (0) days ago, when the stock price was 14.520. Since then the stock gained 0.00% .

Today the stock closed higher with a higher high and a higher low. The volume is low. The security price is trending up and is overbought.

Candlestick Analysis

Today’s Candlestick Patterns:
White Candlestick

Today a White Candlestick formed. Buyers were in control but the buying pressure was not very strong.

Stock Quote
Last 14.520
Previous Close 14.340
Change +0.180
% Change +1.26%
Volume 218,604
Stock Activity
Open 14.340
Day`s High 14.690
Day`s Low 14.220
52 Week High 27.450
52 Week Low 7.590

Stock Price History
3 Month % Change 54.96
6 Month % Change 18.63
12 Month % Change -29.99
Stock Statistics
50 Day Close MA 9.846
200 Day Close MA 12.159
65 Day Volume MA 296,298

JS200

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


03/26/2003 (16:10 ET) New 10-K/A just released for NOVN - Edgar



03/25/2003 (13:02 ET) CONF: NOVN To Present At BOA Healthcare Conference @ 15:45 ET - Knobias



03/24/2003 (11:38 ET) Noven to Present March 25 at Banc of America Securities Healthcare Conference; Public Invited to Listen to Presentation Via Webcast - Business Wire



03/24/2003 (08:34 ET) Noven Discloses Development Programs for Fentanyl and Dextroamphetamine Transdermal Systems - Business Wire



03/21/2003 (16:11 ET) New 10-K just released for NOVN - Edgar



03/10/2003 (06:40 ET) Research and Markets: Noven Pharmaceuticals(NOVN) - Quantitative Valuation Report - M2 Communications



03/07/2003 (09:35 ET) MORNING UPDATE: Man Securities Issues Alerts for GE, AMGN, DDS, TIVO, and NOVN - PR Newswire



03/07/2003 (07:11 ET) Research and Markets: Noven Pharmaceuticals(NOVN) - Quantitative Valuation Report - M2 Communications



03/06/2003 (15:06 ET) VOLUME(+): NOVN Volume 61% > 20-adsv, Stock +9.24% - Knobias



03/06/2003 (06:02 ET) NOVN CEO to Speak at Smith Barney Pharmaceutical Conf. - Knobias



03/05/2003 (11:33 ET) THIRD Business Wire recap for Wed (03/05); stories sent between Wed 10:01 and Wed 11:00 ET (07:01 and 08:00 PT) - Business Wire



03/05/2003 (10:57 ET) Noven Announces Stock Repurchase Program - Business Wire



03/05/2003 (10:50 ET) Noven Pharmaceuticals, Inc. Corrects Date in Press Release, February 28, 2003 Sted February 28, 2002 - Business Wire



03/05/2003 (09:29 ET) Noven Announces Stock Repurchase Program - Business Wire



03/05/2003 (09:24 ET) Noven Announces Stock Repurchase Program - Business Wire



03/03/2003 (15:16 ET) VOLUME(-): NOVN Volume 63% > 20-adsv, Stock -1.29% - Knobias



03/03/2003 (13:30 ET) Noven to Present March 6 at Salomon Smith Barney Specialty Pharmaceuticals Conference; Public Invited to Listen to Presentation Via Webcast - Business Wire



03/03/2003 (07:02 ET) ERN/CALL: NOVN To Hold Q4 Conf Call @ 10:00 ET Today - Knobias


JS200

[JS222]

04/07/2003 (12:17 ET) Noven Announces Closing of MethyPatch License Transaction; Noven Receives $25 Million Closing Payment from Shire - Business Wire
04/01/2003 (15:05 ET) DEF 14A: NOVN Pxy Vote; Elect Directors; Ratify Auditor - Knobias
04/01/2003 (14:16 ET) New DEF 14A just released for NOVN - Edgar
03/26/2003 (16:10 ET) New 10-K/A just released for NOVN - Edgar
03/25/2003 (13:02 ET) CONF: NOVN To Present At BOA Healthcare Conference @ 15:45 ET - Knobias

JS200

[JS222]

Noven Announces Closing of MethyPatch License Transaction; Noven Receives $25 Million Closing Payment from Shire

Monday , April 07, 2003 12:17 ET

MIAMI, Apr 7, 2003 (BUSINESS WIRE) -- Noven Pharmaceuticals, Inc. (Nasdaq:NOVN) today announced that the previously announced transaction licensing its once-daily methylphenidate transdermal system (intended to be marketed as MethyPatch(R)) to Shire Pharmaceuticals Group plc has closed. Noven received $25 million from Shire at closing.

MethyPatch is Noven`s developmental methylphenidate patch for Attention-Deficit Hyperactivity Disorder (ADHD). A New Drug Application for the product, filed with the U.S. Food and Drug Administration in June 2002, is currently under FDA review.

As announced on February 27, in exchange for global rights to MethyPatch, Shire agreed to pay $25 million at closing, $50 million upon receipt of final FDA approval of MethyPatch, and payments of up to $75 million upon achievement of certain MethyPatch sales milestones. For accounting purposes, all payments (including the $25 million closing payment) will be deferred and recognized as Noven revenue over a period of years.

About Noven

Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. Together with Novartis Pharmaceuticals Corporation, Noven owns a profitable women`s health products company called Novogyne Pharmaceuticals. Noven`s existing products include advanced estrogen transdermal delivery systems (including Vivelle-Dot(R), licensed to Novogyne, and Estradot(R), licensed to Novartis Pharma AG) and combination estrogen/progestin transdermal delivery systems (including CombiPatch(R), licensed to Novogyne, and Estalis(R), licensed to Novartis Pharma AG). With a range of additional products in development, including MethyPatch(R), licensed to Shire, Noven is committed to becoming the world`s premier transdermal drug delivery company. For additional information on Noven, visit http://www.noven.com.

This release contains forward-looking information related to the business of Noven that can be identified by the use of forward-looking terminology such as "will" and similar words and phrases. Such statements are qualified by and subject to the risks and uncertainties specified in Noven`s most recent filings with the Securities and Exchange Commission and those specified herein, including the risk that the remaining milestone payments may not be paid if MethyPatch is not approved or if Shire does not achieve the specified sales levels.


CONTACT: Noven Pharmaceuticals, Inc., Miami
Joseph C. Jones, 305/253-1916

URL: http://www.businesswire.com
Today`s News On The Net - Business Wire`s full file on the Internet
with Hyperlinks to your home page.



Copyright (C) 2003 Business Wire. All rights reserved.


-0-


KEYWORD: FLORIDA
INDUSTRY KEYWORD: BANKING
MEDICAL
PHARMACEUTICAL
SOURCE:
Noven
Pharmaceuticals,
Inc.



JS200

[JS222]

Last Trade: 14.420 Change: 0.120 (+0.839%)
Previous Close: 14.300 Volume: 125,300
Bid: 14.420 Ask: 2,499.990
Today`s Open: 14.160 # of Trades: 513

JS200

[JS222]

04/09/2003 (08:34 ET) Noven receives $25 million closing payment from Shire - Datamonitor
04/07/2003 (12:17 ET) Noven Announces Closing of MethyPatch License Transaction; Noven Receives $25 Million Closing Payment from Shire - Business Wire
04/01/2003 (15:05 ET) DEF 14A: NOVN Pxy Vote; Elect Directors; Ratify Auditor - Knobias
04/01/2003 (14:16 ET) New DEF 14A just released for NOVN - Edgar
03/26/2003 (16:10 ET) New 10-K/A just released for NOVN - Edgar

JS200

[JS222]

Von Gestern

NOVN
NOVEN PHARMACEUTICALS INC
14.310
-0.069 -0.48%


Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 4/7/2003 (3) days ago, when the stock price was 14.300. Since then the stock gained 0.07% .

Today the stock closed lower, close to its high (sign of strength) with a lower high and a lower low. The volume is normal. The security price is trending up.

Candlestick Analysis

Today’s Candlestick Patterns:
Spinning Top

Today a Spinning Top formed. Both the bulls and the bears were active during the session. Even though the session opened and closed with little change, prices moved significantly higher and lower in the mean time. Be careful, this indicates weakness among the bulls and a potential change or interruption in the current trend!

Stock Quote
Last 14.310
Previous Close 14.379
Change -0.069
% Change -0.48%
Volume 267,583
Stock Activity
Open 14.280
Day`s High 14.360
Day`s Low 13.850
52 Week High 27.450
52 Week Low 7.590

Stock Price History
3 Month % Change 75.58
6 Month % Change 10.84
12 Month % Change -32.05
Stock Statistics
50 Day Close MA 11.014
200 Day Close MA 11.645
65 Day Volume MA 299,354

JS200

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


04/14/2003 (10:43 ET) SECTOR(HCR): Pharmaceuticals Higher in Early Trading - Knobias



04/11/2003 (15:41 ET) New ARS just released for NOVN - Edgar



04/09/2003 (08:34 ET) Noven receives $25 million closing payment from Shire - Datamonitor



04/07/2003 (12:17 ET) Noven Announces Closing of MethyPatch License Transaction; Noven Receives $25 Million Closing Payment from Shire - Business Wire



04/01/2003 (15:05 ET) DEF 14A: NOVN Pxy Vote; Elect Directors; Ratify Auditor - Knobias



04/01/2003 (14:16 ET) New DEF 14A just released for NOVN - Edgar



03/26/2003 (16:10 ET) New 10-K/A just released for NOVN - Edgar



03/25/2003 (13:02 ET) CONF: NOVN To Present At BOA Healthcare Conference @ 15:45 ET - Knobias



03/24/2003 (11:38 ET) Noven to Present March 25 at Banc of America Securities Healthcare Conference; Public Invited to Listen to Presentation Via Webcast - Business Wire



03/24/2003 (08:34 ET) Noven Discloses Development Programs for Fentanyl and Dextroamphetamine Transdermal Systems - Business Wire



03/21/2003 (16:11 ET) New 10-K just released for NOVN - Edgar

JS200

[js200]

.
http://www.investtech.com/nasdaq/ana/novn.htm

Der Widerstand ist sehr hart, aber nicht uneinnehmbar!!!!!!!!!!!

JS200

[js200]

Noven to Announce First Quarter Financial Results on April 30; Public Invited to Listen to Earnings Conference Call Via Internet
via COMTEX

April 24, 2003

MIAMI, Apr 24, 2003 (BUSINESS WIRE) --

Noven Pharmaceuticals, Inc. (Nasdaq:NOVN), a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products, today announced its first quarter 2003 earnings release date and upcoming investor presentations.

On April 30, before the market opens, Noven is scheduled to issue a press release announcing its financial results for the quarter ended March 31, 2003. Beginning at 11:00 a.m. Eastern Time the same day, a telephone conference among management and analysts will be broadcast live via the Internet at http://www.noven.com, and a rebroadcast will be accessible at the same site. A taped replay of the call will be available by telephone beginning April 30 at noon through May 2 at noon by calling 877-660-6853 (from within the U.S.) or 201-612-7415 (from outside the U.S.) and entering the conference ID# 64158 and the access code 1628.

Noven also announced that Robert Strauss, Noven`s President, CEO and Chairman, is scheduled to make presentations regarding Noven`s business and prospects to the invited guests of:

-- Deutsche Banc Alex. Brown at its 2003 Health Care Conference, May 6-7, in Baltimore, Maryland. -- UBS Warburg at its Global Specialty Pharmaceuticals Conference, June 4-5, in New York, New York.

Questions regarding these conferences should be directed to the host organization.

Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. For additional information on Noven, visit http://www.noven.com.

Noven Pharmaceuticals, Inc., Miami Stefaney Caro, 305/253-1916 http://www.noven.com

http://www.businesswire.com

Today`s News On The Net - Business Wire`s full file on the Internet with Hyperlinks to your home page.

Copyright (C) 2003 Business Wire. All rights reserved.

Print story

Current Quote

NSD: NOVN
Biotech/Medical

Last: 13.500
Change: -0.190
Volume: 378,200
Day High: 13.750
Day Low: 13.440



First Alert News
Get real-time NOVN release alerts by entering your email address below.

JS200

[js200]

UND AUS DIE MAUS

Noven Receives ``Not Approvable``Letter from FDA for Methylphenidate Transdermal System
via COMTEX

April 28, 2003

MIAMI, Apr 28, 2003 (BUSINESS WIRE) --

Noven Pharmaceuticals, Inc. (Nasdaq:NOVN) has received notification from the U.S. Food and Drug Administration (FDA) that the New Drug Application (NDA) for its methylphenidate transdermal system is not approvable. A `not approvable`letter is issued if the FDA believes that the application contains insufficient information for an approval action at the time of issuance. The product is licensed to Shire Pharmaceuticals Group plc.

`We are disappointed with the Agency`s determination, and continue to believe that our product represents a valuable new therapy for the management of Attention Deficit Hyperactivity Disorder,`said Robert Strauss, Noven`s President, CEO &Chairman. `In its letter, the FDA cited clinical and other issues as the basis for non-approval. We are developing our strategy for approval, and plan to meet with the Agency as soon as possible to clarify their concerns and to determine what additional studies, analysis or other actions would resolve the issues raised in the letter.`

Noven will address the FDA letter on its earnings conference call, scheduled for Wednesday, April 30, at 11:00 a.m. The call will be broadcast live via the Internet at http://www.noven.com, and a rebroadcast will be accessible at the same site. A taped replay of the call will be available by telephone beginning April 30 at noon through May 2 at noon by calling 877-660-6853 (from within the U.S.) or 201-612-7415 (from outside the U.S.) and entering the conference ID# 64158 and the access code 1628.

Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. For additional information on Noven, visit www.noven.com.

This release contains forward-looking information related to the business of Noven that can be identified by the use of forward-looking terminology such as `believe,``plan,`and similar words and phrases. Such statements are qualified by and subject to the risks and uncertainties specified in Noven`s most recent filings with the Securities and Exchange Commission and those specified herein, including the risk that Noven may not receive regulatory approvals for MethyPatch, particularly in the United States after the receipt of a `not approvable`letter from the FDA, and that additional clinical studies may be required.

SOURCE: Noven Pharmaceuticals

Noven Pharmaceuticals, Inc. Joseph C. Jones, 305/253-1916

http://www.businesswire.com

Today`s News On The Net - Business Wire`s full file on the Internet with Hyperlinks to your home page.

Copyright (C) 2003 Business Wire. All rights reserved.

JS200

[js200]

Noven Reports First Quarter Earnings Per Share Of $0.02
via COMTEX

April 30, 2003

MIAMI, Apr 30, 2003 (BUSINESS WIRE) --

Noven Pharmaceuticals, Inc. (Nasdaq:NOVN), a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products, today announced financial results for the quarter ended March 31, 2003, and provided an update on its business and prospects.

Financial Results

Noven`s revenues for the first quarter of 2003 (the `current quarter`) were $10.0 million, compared to $12.7 million for the first quarter of 2002 (the `2002 quarter`), reflecting the impact of the Women`s Health Initiative (WHI) study results, published in July 2002, and inventory reduction initiatives intended to align inventories for Noven`s U.S. products with current demand.

Research and development expense decreased compared to the 2002 quarter due to the completion of MethyPatch(R) clinical studies, partially offset by expenses related to development of Noven`s fentanyl patch for chronic pain. Selling, general and administrative expense increased in the current quarter, primarily due to MethyPatch pre-launch marketing expenses. Noven recognized $1.5 million in earnings from Novogyne Pharmaceuticals, Noven`s U.S.-based joint venture with Novartis Pharmaceuticals Corporation (`Novartis`), the same amount recognized in the 2002 quarter.

Noven`s net income was approximately $473,000 ($0.02 diluted earnings per share), compared to $1.5 million ($0.06 diluted earnings per share) in the 2002 quarter.

Novogyne`s revenues were $24.5 million, down 11% from the 2002 quarter, reflecting the continuing impact of WHI and inventory reduction initiatives, partially offset by higher sales of Vivelle-Dot(R), Novogyne`s lead product. Novogyne`s selling, general and administrative expenses decreased to $7.9 million from $9.9 million, primarily due to reduced promotional spending for CombiPatch(R). Novogyne`s net income decreased 2% to $9.4 million, and was sufficient to satisfy Novartis`$6.1 million preferred distribution for 2003.

At March 31, 2003, Noven had cash and cash equivalents of $65.4 million, compared to $58.7 million at December 31, 2002. In April 2003, Noven received $25.0 million from Shire Pharmaceuticals Group plc (Shire) upon closing of the MethyPatch license transaction.

Business Update

`Our strategy is to leverage our patented technology across a diverse range of products and therapeutic categories with different strategic partners, as we work to advance our HRT business,`said Robert Strauss, Noven`s President, CEO &Chairman. `The first four months of 2003 have been productive in this regard.`

-- `We are in the final phase of our U.S. HRT inventory reduction initiatives. We now believe that inventories at Novogyne are at acceptable levels, and that Vivelle inventories in the trade channel remain only modestly higher than desired. We expect to end our inventory reduction initiatives in the 2003 second quarter.` -- `In February, Vivelle-Dot became the market share leader in the U.S. estrogen patch market based on total prescriptions dispensed, and in March it saw the second-highest monthly prescriptions in its history,`said Strauss. `Alone, Vivelle-Dot currently holds 31.7% of the market and, together with original Vivelle(R), it holds 38.4%.` -- `Also in February, we signed an agreement licensing MethyPatch to Shire, the market leader in ADHD therapy. The transaction closed in early April, and we received a $25.0 million payment from Shire. Receipt of a MethyPatch `not approvable`letter from FDA is a set-back, but it does not alter our belief that the product represents a unique and valuable therapy for ADHD.` -- `We disclosed development of a fentanyl patch for chronic pain and a dextroamphetamine patch for ADHD. We also disclosed development of transdermal formulations for over 20 additional compounds that could be developed in partnership with other pharmaceutical companies. Each of these projects incorporate Noven`s patented transdermal technology, and we expect that several will be partnered with other pharmaceutical companies and play a role in Noven`s long-term growth.` -- `And concurrently with this press release, we announced formation of a development collaboration with Procter &Gamble for the development of new transdermal patches targeting a therapeutic category with substantial growth potential.` Conference Call
A conference call relating to Noven`s financial results will be broadcast live at http://www.noven.com beginning at 11:00 a.m. Eastern time this morning, April 30. Thereafter, a rebroadcast will be accessible at the same website. A replay will be available from April 30 at 3:00 p.m. until the evening of May 2 by calling 877-660-6853 (within the U.S.) or 201-612-7415 (outside the U.S.) and entering the access code 64158 and conference ID 1628. The conference call will contain forward-looking information in addition to that contained in this press release.

About Noven

Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. Together with Novartis, Noven owns a profitable women`s health products company called Novogyne Pharmaceuticals. Noven`s existing products include advanced estrogen transdermal delivery systems (including Vivelle-Dot(R), licensed to Novogyne, and Estradot(R), licensed to Novartis Pharma AG) and combination estrogen/progestin transdermal delivery systems (including CombiPatch(R), licensed to Novogyne, and Estalis(R), licensed to Novartis Pharma). With a range of additional products in development, including MethyPatch(R), licensed to Shire, Noven is committed to becoming the world`s premier transdermal drug delivery company. For additional information on Noven, visit http://www.noven.com.

This release contains forward-looking information related to the business of Noven that can be identified by the use of forward-looking terminology such as `could`, `may`, `expect`, `will`, `should`, `potential`, `plan`, `believe`, and similar words and phrases. Such statements are qualified by and subject to the risks and uncertainties specified in Noven`s most recent filings with the Securities and Exchange Commission and those specified herein, including the risk that: we may be unable to attract additional development partners, which would limit our ability to develop additional products; MethyPatch may not be approved, especially in light of our receipt of a `not approvable`letter from FDA; even if approved, MethyPatch may not be successfully commercialized by Shire due to competitive market conditions or other factors, including physician/patient preferences for other ADHD therapies; the timing of FDA approval is outside the control of Noven; the FDA could place limits on permitted marketing claims that could negatively impact MethyPatch`s sales potential; the availability of other once-daily ADHD therapies could negatively impact MethyPatch`s market penetration; Shire may promote its other ADHD products at the expense of MethyPatch; Noven has never manufactured MethyPatch on a commercial scale, and Noven may be unable to supply Shire with its requirements for MethyPatch; if Noven is unable to successfully scale up production of MethyPatch, it may be unable to achieve satisfactory gross margins; the timing of FDA approval may impact the success of the product launch and affect market penetration; Shire may seek to exercise its right to require Noven to repurchase the rights to MethyPatch for $5.0 million; our fentanyl and dextroamphetamine patch development programs, and the development program with Procter &Gamble, may not proceed as expected; we have experienced a production problem with CombiPatch that we believe relates to a material supplied by one vendor, and we believe the problem is resolved; if the problem is not resolved, we may be unable to ship any CombiPatch product, which would have a material adverse effect on our future revenue and earnings; Noven and Novogyne may be unable to align inventories with demand as soon as hoped because of inaccurate estimates, lack of cooperation of third parties or otherwise; unexpected sales deductions or higher product returns at Novogyne could negatively impact Novogyne`s earnings; the U.S. HRT business may be further impacted because of mandated product label changes, the announcement of additional negative clinical results or other reasons; product development is inherently risky and Noven may be unable to advance its other development projects; Noven`s HRT business may decline further than expected in 2003, whether as a continuing result of WHI and other studies announced in 2002 or otherwise; there can be no assurance that Noven will receive any additional payments from Shire or that if additional payments are received, that we will utilize the funds expected to be received in the Shire transaction in a manner that will increase long-term shareholder value.

Noven Pharmaceuticals, Inc.Statements of Operations Data: Three Months Ended(amounts in thousands, except March 31,per share amounts) 2003 2002 ----------- ----------- (Unaudited) (Unaudited)Revenues: Product sales $9,144 $11,991 License revenue 881 744 ----------- ----------- Total revenues 10,025 12,735Expenses: Cost of products sold 4,285 5,900 Research and development 2,493 3,369 Marketing, general and administrative 4,181 2,933 ----------- ----------- Total expenses 10,959 12,202 ----------- -----------Income (loss) from operations (934) 533Equity in earnings of Novogyne 1,525 1,515Interest income, net 148 207 ----------- -----------Income before income taxes 739 2,255Provision for income taxes 266 802 ----------- -----------Net income $473 $1,453 =========== ===========Basic earnings per share $0.02 $0.06 =========== ===========Diluted earnings per share $0.02 $0.06 =========== ===========Weighted average number of common shares outstanding: Basic 22,581 22,491 =========== =========== Diluted 22,920 23,456 =========== =========== As Of ----------------------- March 31, December 31,Balance Sheet Data: 2003 2002 ----------- ----------- (Unaudited) (Unaudited) Cash and cash equivalents $65,404 $58,684 Investment in Novogyne $25,561 $34,684 Total assets $135,345 $137,702 Deferred license revenue $28,564 $29,445 Stockholders`equity $96,048 $96,741
SOURCE: Noven Pharmaceuticals, Inc.

Noven Pharmaceuticals, Inc., Miami Investor &Media Contact: Joseph C. Jones, 305/253-1916

http://www.businesswire.com

Today`s News On The Net - Business Wire`s full file on the Internet with Hyperlinks to your home page.

Copyright (C) 2003 Business Wire. All rights reserved.

JS200

[js200]

Noven Signs Transdermal Development Agreement With Procter & Gamble Company
via CDS

April 30, 2003

Noven Pharmaceuticals, Inc. (Nasdaq:NOVN) today announced that it has signed an agreement to develop new prescription transdermal delivery systems for P&G Pharmaceuticals, Inc. (P&G), a subsidiary of The Procter & Gamble Company. Under the agreement, Noven is entitled to receive up to $7.8 million, payable in installments if certain development milestones are achieved. Development efforts under the agreement are expected to continue through 2004. `We are very pleased to establish a development collaboration with the emerging pharmaceutical unit of one of the world`s largest consumer products companies,`said Robert Strauss, Noven`s President, CEO & Chairman. `Although we have not disclosed the compounds incorporated in the new patches, they target a therapeutic category with outstanding commercial potential.``P&G`s selection of Noven as its development partner further validates our technology and advances our business diversification strategy. With a product pipeline that includes dextroamphetamine and fentanyl patches, as well as over 20 other formulated patch products, we are optimistic that additional development collaborations lay ahead.`About Noven Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. Together with Novartis Pharmaceuticals Corporation, Noven owns a profitable women`s health products company called Novogyne Pharmaceuticals. Noven`s existing products include advanced estrogen transdermal delivery systems (including Vivelle-Dot(R), licensed to Novogyne, and Estradot(R), licensed to Novartis Pharma AG) and combination estrogen/progestin transdermal delivery systems (including CombiPatch(R), licensed to Novogyne, and Estalis(R), licensed to Novartis Pharma AG). With a range of additional products in development, including MethyPatch(R) for ADHD (licensed to Shire Pharmaceuticals Group plc), Noven is committed to becoming the world`s premier transdermal drug delivery company. For further information on Noven, including product licensing opportunities, visit http://www.noven.com.



CONTACT: Noven Pharmaceuticals, Inc., Miami
Investor & Media Contact:
Joseph C. Jones, 305/253-1916
or
Product Licensing Inquiries:
Pavan Handa, 305/964-3330


JS200

[js200]

Noven Announces Availability of Clinical Data on Transdermal Combination Hormone Therapy
via COMTEX

May 1, 2003

MIAMI, May 1, 2003 (BUSINESS WIRE) --

Noven Pharmaceuticals, Inc. (Nasdaq:NOVN) today announced the availability of clinical data examining the effects of transdermal combination hormone replacement therapy (HRT) on the sexual quality of life of postmenopausal women and on renin substrate levels, which may impact blood pressure.

Separate posters entitled `CombiPatch(R) Significantly Improves Women`s Sexual Quality of Life Compared to Prempro(R) in a Randomized Trial`and `Renin Substrate Levels Decrease With Transdermal Hormone Therapy and Increase With Oral Hormone Therapy`were recently presented at a national medical conference. The data was presented by James A. Simon M.D., of George Washington University; Rebecca G. Rogers, M.D., of the University of New Mexico; and Vanaja V. Rgavan M.D., of Novartis Pharmaceuticals Corporation. Copies of the poster presentations are available at http://www.noven.com under `Research - Scientific Publications.`

Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products, including the only combination HRT patch available in the United States. For additional information on Noven, visit http://www.noven.com. Prempro(R) is a registered trademark of Wyeth Pharmaceuticals; CombiPatch(R) is a registered trademark of Novogyne Pharmaceuticals.

SOURCE: Noven Pharmaceuticals, Inc.

Noven Pharmaceuticals, Inc., Miami Joseph C. Jones, 305/253-1916

http://www.businesswire.com

Today`s News On The Net - Business Wire`s full file on the Internet with Hyperlinks to your home page.

Copyright (C) 2003 Business Wire. All rights reserved.

JS200

[Heinerle2]

@js200: Im Nachhinein war es doch richtig, auszusteigen, ich hoffe, Du hattest auch mal Gewinne mitgenommen. IN den letzten Tagen habe ich mich besonders an meinen OSI Pharma, D&K Health (Verkauf 29.04.), Arqule und Xenova erfreut. TKTX, REGN und EMBX wollen noch nicht so recht

Greetinxx Heinerle2 - NOVN wieder auf Watchlist habend

[js200]

Noven to Present at Deutsche Bank Securities Health Care Conference
via COMTEX

May 2, 2003

MIAMI, May 2, 2003 (BUSINESS WIRE) --

Noven Pharmaceuticals, Inc. (Nasdaq:NOVN) announced that Robert Strauss, its President, CEO & Chairman, will make a presentation regarding Noven`s business and prospects on Tuesday, May 6 at 9:00 a.m. Eastern time at the Deutsche Bank Securities 28th Annual Health Care Conference in Baltimore, Maryland. A live webcast of the presentation will be accessible to the public at http://www.noven.com, and a rebroadcast will be available thereafter.

Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. Noven`s existing products include advanced estrogen transdermal delivery systems and combination estrogen/progestin transdermal delivery systems. With a range of additional products in development, Noven is committed to becoming the world`s premier developer, manufacturer and marketer of transdermal drug delivery systems. For additional information on Noven, visit http://www.noven.com.

SOURCE: Noven Pharmaceuticals, Inc.

Noven Pharmaceuticals, Inc., Miami Stefaney Caro, 305/253-1916

http://www.businesswire.com

Today`s News On The Net - Business Wire`s full file on the Internet with Hyperlinks to your home page.

Copyright (C) 2003 Business Wire. All rights reserved.

JS200

[js200]

@HEINERLE

Hatte ein Limit mit 28% plus und war draussen

JS200

[js200]

http://www.investtech.com/nasdaq/ana/novn.htm

JS200

[js200]

Noven to Hold Annual Shareholders`Meeting on May 14; Public Invited to Listen to Webcast of Meeting
via COMTEX

May 12, 2003

MIAMI, May 12, 2003 (BUSINESS WIRE) --

Noven Pharmaceuticals, Inc. (Nasdaq:NOVN), a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products, will hold its Annual Meeting of Shareholders`on May 14, 2003, at 10:00 a.m. at Noven corporate headquarters, 11960 SW 144th Street, Miami, Florida. Live audio of the meeting will be available at http://www.noven.com, and a rebroadcast will be available at the same site. Please visit the site at least 15 minutes in advance to download any required software.

Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. Together with Novartis Pharmaceuticals Corporation, Noven owns a profitable women`s health products company called Novogyne Pharmaceuticals. Noven`s existing products include advanced estrogen transdermal delivery systems (including Vivelle-Dot(R), licensed to Novogyne, and Estradot(R), licensed to Novartis Pharma AG) and combination estrogen/progestin transdermal delivery systems (including CombiPatch(R), licensed to Novogyne, and Estalis(R), licensed to Novartis Pharma AG). With a range of additional products in development, Noven is committed to becoming the world`s premier transdermal drug delivery company. For additional information, visit Noven`s website at http://www.noven.com.

SOURCE: Noven Pharmaceuticals, Inc.

Noven Pharmaceuticals, Inc., Miami Investor &Media: Joseph C. Jones, 305/253-1916

http://www.businesswire.com

Today`s News On The Net - Business Wire`s full file on the Internet with Hyperlinks to your home page.

Copyright (C) 2003 Business Wire. All rights reserved.

JS200

[js200]

Von Gestern

NOVN
NOVEN PHARMACEUTICALS INC
9.790
+0.100 +1.03%


Daily Commentary
BUY

Our system recommends BUY as of today. Previous SELL recommendation was made on 4/7/2003 (35) days ago, when the stock price was 14.300. Since then the stock fell -31.54% .

Today the stock closed higher with a higher high and a higher low. The volume is extremely low. The security price is trending sideways.


Long-term trend is bearish, but the downward move seems to have stopped. A reaction rally has started which may shortly turn into a bull trap. On the other hand, this may be the reversal point of the long-term downtrend. You may buy this stock now, but be careful!

Candlestick Analysis

Today’s Candlestick Patterns:
Spinning Top

Today a Spinning Top formed. Both the bulls and the bears were active during the session. Even though the session opened and closed with little change, prices moved significantly higher and lower in the mean time. Be careful, this indicates weakness among the bears and a potential change or interruption in the current trend!

Stock Quote
Last 9.790
Previous Close 9.690
Change +0.100
% Change +1.03%
Volume 218,156
Stock Activity
Open 9.740
Day`s High 9.850
Day`s Low 9.660
52 Week High 27.450
52 Week Low 7.590

Stock Price History
3 Month % Change 18.09
6 Month % Change -7.29
12 Month % Change -53.00
Stock Statistics
50 Day Close MA 12.537
200 Day Close MA 11.164
65 Day Volume MA 548,755

JS200

[js200]

Noven Announces Annual Meeting Results; Diane M. Barrett Appointed Chief Financial Officer
via COMTEX

May 15, 2003

MIAMI, May 15, 2003 (BUSINESS WIRE) --

Noven Pharmaceuticals, Inc. (Nasdaq:NOVN) today announced the results of its 2003 Annual Meeting of Shareholders and the appointment of Diane M. Barrett (previously Noven`s Vice President - Finance &Treasurer) as Vice President & Chief Financial Officer.

Shareholder Meeting Results

The holders of over 90% of Noven`s common stock were represented in person or by proxy at the meeting, held May 14 at the company`s headquarters in Miami Florida. Shareholders re-elected the following persons to the Noven Board of Directors:

-- Sidney Braginsky (President &CEO of Atropos Technology Inc.); -- John G. Clarkson, M.D. (Senior Vice President for Medical Affairs &Dean, University of Miami School of Medicine); -- Lawrence J. DuBow (Chairman, HMS Sales and Marketing, Inc.); -- Regina E. Herzlinger (Prof. of Business Administration, Harvard Business School); -- Robert C. Strauss (President, CEO &Chairman of Noven); and -- Wayne P. Yetter (CEO &Chairman, SYNAVANT, Inc.).
Shareholders also ratified the appointment of Deloitte &Touche LLP as Noven`s independent auditors for 2003. At the meeting, Robert Strauss made a presentation regarding Noven`s business and prospects. A replay of the meeting is available at http://www.noven.com.

Appointment of CFO

Noven also announced that its Board of Directors has appointed Diane M. Barrett as Noven`s Vice President &Chief Financial Officer. Ms. Barrett, a Certified Public Accountant with over 20 years finance and accounting experience, joined Noven in August 2000, and served most recently as Vice President - Finance &Treasurer. She assumed the office of Chief Financial Officer from James B. Messiry. Mr. Messiry has been appointed Senior Vice President, retaining responsibility for the company`s transaction-related initiatives geared toward product and partner diversification and other corporate objectives.

About Noven

Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. Together with Novartis Pharmaceuticals Corporation, Noven owns a profitable women`s health products company called Novogyne Pharmaceuticals. Noven`s existing products include advanced estrogen transdermal delivery systems (including Vivelle-Dot(R), licensed to Novogyne, and Estradot(R), licensed to Novartis Pharma AG) and combination estrogen/progestin transdermal delivery systems (including CombiPatch(R), licensed to Novogyne, and Estalis(R), licensed to Novartis Pharma AG). With a range of additional products in development, Noven is committed to becoming the world`s premier transdermal drug delivery company.

SOURCE: Noven Pharmaceuticals, Inc.

Noven Pharmaceuticals, Inc., Miami Joseph C. Jones, 305/253-1916 http://www.noven.com

http://www.businesswire.com

Today`s News On The Net - Business Wire`s full file on the Internet with Hyperlinks to your home page.

Copyright (C) 2003 Business Wire. All rights reserved.

JS200

[js200]

http://www.investtech.com/nasdaq/ana/novn.htm

JS200

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


06/03/2003 (16:11 ET) VOLUME(+): NOVN Volume 87% > 20-adsv, Stock +7.42% - Knobias



05/30/2003 (09:25 ET) SECTOR(HCR): Prudential Updates Cancer Pharm. Cos. - Knobias



05/28/2003 (13:34 ET) NOVN: Short Interest UP 12.0% to 710.6K in May 2003 - Knobias



05/22/2003 (07:30 ET) CardioGenesis Holds Annual Meeting - PR Newswire



05/20/2003 (11:22 ET) SECTOR(HCR): Pharmaceutical Stks Still Under Pressure - Knobias



05/20/2003 (08:50 ET) SECTOR(HCR): CSFB Downgrades Pharmaceuticals - Knobias



05/15/2003 (14:52 ET) New 4 just released for NOVN - Edgar



05/15/2003 (14:29 ET) New 4 just released for NOVN - Edgar



05/15/2003 (14:15 ET) New 4 just released for NOVN - Edgar



05/15/2003 (14:07 ET) New 4 just released for NOVN - Edgar



05/15/2003 (09:03 ET) Noven Announces Annual Meeting Results; Diane M. Barrett Appointed Chief Financial Officer - Business Wire



05/14/2003 (16:55 ET) New 10-Q just released for NOVN - Edgar



05/14/2003 (07:02 ET) DEF 14A: NOVN Pxy Vote; Elect Directors; Ratify Auditor - Knobias



05/12/2003 (13:02 ET) Noven to Hold Annual Shareholders` Meeting on May 14; Public Invited to Listen to Webcast of Meeting - Business Wire



05/06/2003 (15:09 ET) New 8-K just released for NOVN - Edgar

JS200

[js200]

http://www.investtech.com/nasdaq/ana/novn.htm

JS200

[js200]

Noven Announces Second Quarter Financial Results
via COMTEX

July 31, 2003

MIAMI, Jul 31, 2003 (BUSINESS WIRE) --

U.S. HRT Inventories Reach Desired Levels Prescriptions for Noven`s U.S. Products Increase 2.5% Over 2003 First Quarter

Noven Pharmaceuticals, Inc. (Nasdaq:NOVN), a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products, today announced financial results for the quarter and six months ended June 30, 2003, and provided an update on its business and prospects.

Financial Results Second Quarter 2003

Noven`s revenues for the second quarter of 2003 (the `current quarter`) were $12.3 million, compared to $16.2 million for the second quarter of 2002 (the `2002 quarter`). The year-over-year decline reflects the impact of the Women`s Health Initiative (WHI) studies on Noven`s products, and lower international sales due to launch delays for Estradot and declines in volume for Noven`s other international products. `The second quarter of 2002 was the strongest in the history of our hormone replacement therapy (HRT) business, and comparisons to that quarter reflect the continuing impact of WHI,`said Robert Strauss, Noven`s President, CEO &Chairman. `However, although it may not enjoy its prior growth rate, our U.S. HRT business remains highly profitable and should continue to help fund our pipeline products and allow us to diversify Noven into new areas of growth.`

In the current quarter, Noven`s gross margin declined due to lower production volumes, lower royalties from Novogyne Pharmaceuticals (Noven`s women`s health products company owned jointly with Novartis Pharmaceuticals Corporation), and higher deferred profit on sales to Novogyne. Because Noven owns 49% of Novogyne, it defers 49% of profit on product sold to Novogyne until that product sells through to the trade. Noven did not ship CombiPatch to Novogyne in the 2003 first quarter due to a production issue. Noven resumed CombiPatch shipments to Novogyne late in the second quarter, but much did not sell through before quarter-end, causing Noven`s deferred profit to increase and its gross margin to decline.

Research and development expense decreased 35% compared to the 2002 quarter due to the completion of MethyPatch Phase III clinical studies, partially offset by development expenses for Noven`s fentanyl patch for chronic pain. Marketing, general and administrative expense decreased 10% in the current quarter, primarily due to a reduction in MethyPatch pre-launch marketing expenses following the license of that product to Shire Pharmaceuticals Group plc (Shire).

Noven recognized $3.8 million in earnings from Novogyne, compared to $7.1 million in the 2002 quarter. Noven`s net income was $3.1 million ($0.13 diluted earnings per share), compared to $6.6 million ($0.28 diluted earnings per share) in the 2002 quarter.

Novogyne`s revenues were $22.2 million, down 33% from the 2002 quarter, reflecting the continuing impact of WHI, previously-announced inventory reduction initiatives, and fluctuations in timing of Vivelle-Dot purchases by trade participants. Novogyne`s selling, general and administrative expenses decreased 2% to $8.1 million, and Novogyne`s net income decreased 47% to $8.2 million.

`During the fourth quarter of 2002 and first half of this year, we undertook inventory reduction initiatives intended to align inventories of our U.S. products with the reduced demand that followed WHI,`said Strauss. `We believe that, subject to normal fluctuations, inventories at Novogyne and in the trade channel have now reached desired levels.`

First Half 2003

Noven`s revenues for the first six months of 2003 (the `current period`) were $22.3 million, compared to $28.9 million for the first six months of 2002 (the `2002 period`), reflecting the impact of WHI and lower international sales.

Gross margin declined due to lower production volumes, lower royalties from Novogyne, and increased deferred profit on sales to Novogyne. Research and development expense decreased 30% compared to the 2002 period, largely due to the completion of MethyPatch Phase III clinical studies. Marketing, general and administrative expense increased 13% in the current period, primarily due to pre-launch MethyPatch marketing expenses incurred prior to the Shire license.

Noven recognized $5.3 million in earnings from Novogyne, compared to $8.6 million in the 2002 period. Noven`s net income was $3.5 million ($0.15 diluted earnings per share), compared to $8.1 million ($0.34 diluted earnings per share) in the 2002 period.

Novogyne`s revenues for the 2003 first half were $46.7 million, down 23% from the 2002 period, reflecting the continuing impact of WHI, inventory reduction initiatives, and fluctuations in timing of trade purchases for Vivelle-Dot. Novogyne`s selling, general and administrative expenses decreased 12% to $15.9 million, due primarily to lower CombiPatch promotional spending. Net income decreased 30% to $17.6 million.

At June 30, 2003, Noven had cash and cash equivalents of $83.8 million compared to $58.7 million at December 31, 2002. In April 2003, Noven received $25.0 million from Shire upon closing of the MethyPatch license transaction.

U.S. Prescription Update One Year Following WHI

In the year following publication of initial data from WHI (July 9, 2002), the U.S. HRT market has declined 26.3% compared to the 12 months that preceded it. For the same period, aggregate prescriptions for Noven`s U.S. products (Vivelle, Vivelle-Dot and CombiPatch) have decreased 2.6%. Vivelle family prescriptions have increased 2.8%, while the estrogen segment of the HRT market has declined 21.0%, and Vivelle-Dot, which represents almost 70% of Noven`s total U.S. prescriptions, increased 15.8%. At mid-year 2003, the Vivelle family held a 39.7% share of total estrogen patch prescriptions, compared to a 34.9% share at mid-year 2002, extending the Vivelle family`s lead as the most dispensed estrogen patch franchise in the U.S.

Prescriptions for Noven`s CombiPatch declined 20.7% in the year following WHI, while the fixed combination hormone therapy segment declined 43.6%. At mid-year 2003, CombiPatch had increased its share of total prescriptions in the fixed combination segment to 4.5% from 2.6% at mid-year 2002.

Sequential Quarter Improvement

`Aggregate prescriptions for Noven`s products increased 2.5% in the second quarter compared to the 2003 first quarter, while total prescriptions for HRT products as a whole declined 4.8%,`said Strauss. `That is encouraging progress in this post-WHI environment, reflecting the quality of our products and the effectiveness of the Novogyne sales force.`

Business Update

`Our principal objective is to advance our new product pipeline and leverage our patented DOT Matrix(TM) technology across multiple therapeutic categories with a range of commercial partners,`said Strauss. `We expect profits from our HRT business to continue to help support these critical diversification efforts.`

`In the category of Attention Deficit Hyperactivity Disorder, Noven and Shire are working with the FDA to address issues raised in the not approvable letter received with respect to MethyPatch,`said Strauss. `We are conducting additional data analyses of MethyPatch clinical studies in an effort to address the FDA`s clinical issues without undertaking an additional pre-approval study. In parallel with that analysis, we also expect to begin a large-scale clinical study before year-end, reflecting our belief that additional clinicals are likely to be required prior to approval.`

`In the pain management category, we are on schedule to file an Abbreviated New Drug Application this summer for a fentanyl transdermal system that would be the generic equivalent of Johnson & Johnson`s Duragesic(R), which had U.S. sales of over $900 million in 2002. Discussions continue with potential partners, and we have formulated additional transdermal pain products that may help expand our prospects in pain management.`

`With Procter &Gamble, we are progressing toward various development milestones for new prescription patches in an undisclosed therapeutic category. If approved, the resulting products could join our fentanyl patch and MethyPatch as potential growth drivers in the years to come.`

`In addition, we are meeting with a number of companies seeking to enhance their prescription compounds or extend product life cycles using Noven`s patented technologies,`said Strauss. `We are committed to establishing additional collaborations in the quarters to come, each with the potential to contribute diversity, stability and incremental growth to our business.`

Outlook

For full-year 2003, Noven expects to report revenues in the low $40 million range, reflecting prior public guidance indicating that lower sales of its international products and CombiPatch were expected to cause revenues in the second half of 2003 to be lower than the first. Depending on the cost and timing of expected MethyPatch clinical trials, Noven`s diluted earnings per share for 2003 could be as low as $0.30.

Conference Call

A conference call relating to Noven`s financial results will be broadcast live via the Internet at http://www.noven.com beginning at 11:00 a.m. Eastern time this morning, July 31. Thereafter, a rebroadcast of the call will be accessible at the same website. A taped replay will be available from July 31 in the afternoon through August 2 by calling 877-660-6853 (from within the U.S.) or 201-612-7415 (from outside the U.S.) and entering the access code 1628 and conference ID 71559. The conference call will contain material forward-looking information in addition to that contained in this press release.

About Noven

Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. Together with Novartis, Noven owns a profitable women`s health products company called Novogyne Pharmaceuticals. Noven`s existing products include advanced estrogen transdermal delivery systems (including Vivelle-Dot(R), licensed to Novogyne, and Estradot(R), licensed to Novartis Pharma AG) and combination estrogen/progestin transdermal delivery systems (including CombiPatch(R), licensed to Novogyne, and Estalis, licensed to Novartis Pharma). With a range of additional products in development, Noven is committed to becoming the world`s premier transdermal drug delivery company. For additional information on Noven, visit http://www.noven.com.

This release contains forward-looking information related to the business of Noven that can be identified by the use of forward-looking terminology such as `should`, `believe`, `expect`, `will`, `likely`, `may`, `could`, and similar words and phrases. Such statements are qualified by and subject to the risks and uncertainties specified in Noven`s most recent filings with the Securities and Exchange Commission and those specified herein, including the risk that: we may be unable to attract additional development partners, which would limit our ability to develop additional products; our regulatory strategies may not be successful in addressing the issues raised by FDA in the MethyPatch not approvable letter, and MethyPatch may not be approved; planned MethyPatch clinical studies may not commence on schedule or at all due to recruiting or other issues, and/or they may be more costly or of longer duration than currently estimated; if approved, MethyPatch may not be successfully commercialized by Shire due to competitive market conditions or other factors, including physician/patient preferences for other ADHD therapies; the timing of FDA approval is outside the control of Noven; the FDA could place limits on permitted marketing claims that could negatively impact MethyPatch`s sales potential; the availability of other once-daily ADHD therapies could negatively impact MethyPatch`s market penetration; the timing of any FDA approval may impact the success of the product launch and affect market penetration; our fentanyl and Procter &Gamble development programs may not proceed on schedule or as expected; patent or other strategies by third parties could delay or prevent the launch of Noven`s fentanyl patch; Noven may not achieve development milestones or complete development of new products under the Proctor &Gamble collaboration; inventory estimates may not be accurate and therefore inventories for Noven`s products may be higher than estimated; unexpected sales deductions or higher product returns at Novogyne could negatively impact Novogyne`s earnings; the U.S. HRT business may be further impacted because of mandated product label changes, the announcement of additional negative clinical results or other reasons, which could reduce or eliminate any Novogyne profit contribution to Noven; product development is inherently risky and Noven may be unable to advance its other development projects; Noven`s HRT business may fail to grow at expected rates or may decline in 2003, whether as a continuing result of WHI and other studies announced in 2002 or otherwise; Noven`s estimates for expected 2003 revenues and earnings may prove to be inaccurate due to higher than estimated MethyPatch clinical expenses, lower than expected product sales in the U.S. or abroad, and other factors.

Noven Pharmaceuticals, Inc.Statements of Three Months Six MonthsOperations Data: Ended Ended(amounts in thousands, June 30, June 30, except --------------------- ---------------------- per share amounts) 2003 2002 2003 2002 --------- --------- --------- --------- (Unaudited)(Unaudited)(Unaudited)(Unaudited)Revenues: Product revenues - Novogyne $7,054 $8,420 $11,215 $16,079 Product revenues - third parties 3,786 6,058 8,743 9,835 --------- --------- --------- --------- Total product revenues 10,840 14,478 19,958 25,914 License and contract revenues 1,421 1,678 2,328 2,977 --------- --------- --------- --------- Total revenues 12,261 16,156 22,286 28,891Expenses: Cost of products sold 6,040 6,021 10,325 11,921 Research and development 2,154 3,313 4,647 6,682 Marketing, general and administrative 3,293 3,679 7,474 6,612 --------- --------- --------- --------- Total expenses 11,487 13,013 22,446 25,215 --------- --------- --------- --------- Income from operations 774 3,143 (160) 3,676Equity in earnings of Novogyne 3,795 7,132 5,320 8,647Interest income, net 198 195 346 402 --------- --------- --------- ---------Income before income taxes 4,767 10,470 5,506 12,725Provision for income taxes 1,717 3,827 1,983 4,629 --------- --------- --------- ---------Net income $3,050 $6,643 $3,523 $8,096 ========= ========= ========= =========Basic earnings per share $0.14 $0.29 $0.16 $0.36 ========= ========= ========= =========Diluted earnings per share $0.13 $0.28 $0.15 $0.34 ========= ========= ========= =========Weighted average number of common shares outstanding: Basic 22,493 22,528 22,536 22,510 ========= ========= ========= ========= Diluted 22,937 23,687 22,928 23,571 ========= ========= ========= ========= As Of ------------------------ June 30, December 31,Balance Sheet Data: 2003 2002 ---------- ------------ (Unaudited) (Unaudited) Cash and cash equivalents $83,789 $58,684 Investment in Novogyne $26,353 $34,684 Total assets $168,276 $137,702 Deferred license revenues $52,182 $29,445 Stockholders`equity $99,170 $96,741
SOURCE: Noven Pharmaceuticals, Inc.

Noven Pharmaceuticals, Inc., Miami Joseph C. Jones, 305/253-1916 http://www.noven.com

http://www.businesswire.com

Today`s News On The Net - Business Wire`s full file on the Internet with Hyperlinks to your home page.

Copyright (C) 2003 Business Wire. All rights reserved.


JS200

[js200]

08/15/2003 (08:27 ET) DRG: R. James Comments on Drug Co`s Receivables - Knobias
08/14/2003 (12:39 ET) New 10-Q just released for NOVN - Edgar
08/13/2003 (10:08 ET) PHARMACEUTICALS: R. James Comments on Industry - Knobias
08/12/2003 (06:14 ET) MEDIA: Today`s Wall Street Journal Mentions NOVN - Knobias
08/11/2003 (14:49 ET) PHARMA: R. James Comments on Weekly Prescriptions Sales - Knobias

JS200

[js200]

Twelve Months Free Cash Flow Turns Positive for Noven Pharmaceuticals
via CDS

September 1, 2003

CashFlowNews.com reports that Free Cash Flow for Noven Pharmaceuticals Inc (NASDAQ:NOVN) for its twelve months ended June 30, 2003 was a positive $43,423,000, compared with a negative Free Cash Flow of $(974,000) for the comparable year earlier twelve months. Free Cash Flow for the most recent twelve months also reached a seven year high.



For Noven Pharmaceuticals`quarter ended June 30, 2003 Free Cash Flow was $18,416,000, compared with $(5,959,000). Noven Pharmaceuticals has generated four consecutive quarters of positive Free Cash Flow. Free Cash Flow for the most recent quarter also reached a eight year high.



The shares of Noven Pharmaceuticals were recently trading at $11.28.



Free Cash Flow defined by CashFlowNews.com:



Free cash flow is defined as cash flow from operations or operating cash flow plus or minus capital expenditures. `Capital Expenditures`is a line item, which can be found in the Cash Flow From Investments section of a company`s Cash Flow Statement which is filed quarterly with the SEC.



CashFlowNews.com is the primary `cash flow`news source for over 10,000public companies, monitoring and reporting on EBITDA, Cash Flow fromOperations (CFFO) and Free Cash Flow (FCF).



CashFlowNews also features cash flow related stories from other sources suchas financial magazines, news letters and rating services, etc. For moreinformation on how to subscribe to CashFlowNews.com call 941-351-3004 ore-mail [e-mail].

JS200